PUBLIC COMPANY
save$IMCRImmunocore Holdings plc
$IMCR36.28-1.57%Oxfordshire, GBupdated 8h ago
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology.
community read0 votes
pipeline
1
marketed
1
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Marketed
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1Study of IMC-S118AI in Type 1 Diabetes
- phase2Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
- phase2Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors
- phase1Study of IMC-P115C in Advanced PRAME-Positive Cancers
- phase3Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- phase3IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- phase2Phase 1/2 Study of IMC-R117C in Selected Advanced Cancers
- phase2Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab
🐶 Hiring Signal
next earnings Nov 5, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that